Business Standard

Monday, December 23, 2024 | 10:47 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Cipla to price Covid-19 drug remdesivir at less than Rs 5,000 per vial

Hyderbad-based drug firm Hetero on Sunday said that it will price its generic version of the drug in the range of Rs 5,000-6,000 per dose

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
Premium

In May, domestic pharma firms Hetero, Cipla and Jubilant Life Sciences entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of remdesivir

Press Trust of India New Delhi
Pharma major Cipla will price its generic version of antiviral drug remdesivir at less than Rs 5,000 per vial in keeping with its conviction of providing access to the medicines at affordable cost, the company said on Tuesday.
"In line with our overall philosophy of driving access and affordability, the drug will be priced at less than Rs 5,000 per vial vial for injection 100 mg -- amongst the lowest pricing for remdesivir globally," Cipla said in an e-mailed response to PTI.
On being asked about the launch of the drug, the company said: "We have started commercial manufacturing, and the product

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in